For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 2,392,658 | |||
| General and administrative | 6,969,845 | |||
| Total operating expenses | 9,362,503 | |||
| Loss from operations | -9,362,503 | |||
| Interest income | 182,229 | |||
| Interest expense | 785,930 | |||
| Foreign currency exchange, net | -13,193 | |||
| Total other income (expense), net | -616,894 | |||
| Loss before income taxes | -9,979,397 | |||
| Income tax benefit | -136,910 | |||
| Net loss | -9,842,487 | |||
| Basic EPS | -4.56 | |||
| Diluted EPS | -4.56 | |||
| Basic Average Shares | 2,157,076 | |||
| Diluted Average Shares | 2,157,076 | |||
ORAGENICS INC (OGEN)
ORAGENICS INC (OGEN)